<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01242917</url>
  </required_header>
  <id_info>
    <org_study_id>CL004_354</org_study_id>
    <secondary_id>2010-019964-36</secondary_id>
    <nct_id>NCT01242917</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Safety and Efficacy of CCX354-C in Subjects With Rheumatoid Arthritis Partially Responsive to Methotrexate Therapy</brief_title>
  <acronym>CARAT-2</acronym>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Safety and Efficacy of CCX354-C in Subjects With Rheumatoid Arthritis Partially Responsive to Methotrexate Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ChemoCentryx</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ChemoCentryx</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, double-blind, placebo-controlled, Phase 2 study to evaluate the safety&#xD;
      and efficacy of CCX354-C in subjects with rheumatoid arthritis partially responsive to&#xD;
      methotrexate therapy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2010</start_date>
  <completion_date type="Actual">July 2011</completion_date>
  <primary_completion_date type="Actual">July 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Subject incidence of adverse events</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The change from baseline to week 12 of Disease Activity Score for 28 Joints using C-reactive proteine (DAS28-CRP)</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">159</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>CCX354-C 100mg twice daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>CCX354-C 200mg once daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CCX-354-C</intervention_name>
    <description>200mg film-coated tablets once daily for 12 weeks + Methotrexate</description>
    <arm_group_label>CCX354-C 200mg once daily</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo film-coated tablets twice daily for 12 weeks + methotrexate</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CCX354-C</intervention_name>
    <description>100mg film-coated tablets twice daily for 12 weeks + methotrexate</description>
    <arm_group_label>CCX354-C 100mg twice daily</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female subjects, aged 18-75 years inclusive, with functional class I to III&#xD;
             rheumatoid arthritis (RA) based on American College of Rheumatology (ACR) criteria for&#xD;
             at least 3 months prior to screening; wheel-chair bound subjects or those with&#xD;
             irreversible disease will not be eligible;&#xD;
&#xD;
          2. Subjects must have active RA, defined by a minimum of 8 swollen joints and 8&#xD;
             tender/painful joints (based on 66/68 joint count), at screening&#xD;
&#xD;
          3. Serum C-reactive protein (CRP) above 5 mg/L at screening;&#xD;
&#xD;
          4. Must have been on methotrexate (7.5 to 25 mg/week) taken orally, subcutaneously, or&#xD;
             intramuscularly for ≥ 16 weeks and on a stable dose for ≥ 8 weeks prior to&#xD;
             randomization;&#xD;
&#xD;
          5. If on hydroxychloroquine, must have been on a stable dose for ≥ 16 weeks prior to&#xD;
             randomization;&#xD;
&#xD;
          6. If taking non-steroidal anti-inflammatory drugs (NSAIDs), must have been on stable&#xD;
             doses for ≥ 2 weeks before randomization;&#xD;
&#xD;
          7. If taking oral corticosteroids, subjects may not take more than 10 mg/day of&#xD;
             prednisone or equivalent, and must have been on a stable dose for ≥ 4 weeks before&#xD;
             randomization;&#xD;
&#xD;
          8. Willing and able to give written Informed Consent and to comply with the requirements&#xD;
             of the study protocol;&#xD;
&#xD;
          9. Negative result of the human immunodeficiency virus (HIV) screen, the hepatitis B&#xD;
             screen, and the hepatitis C screen;&#xD;
&#xD;
         10. Judged to be otherwise healthy by the Investigator, based on medical history, physical&#xD;
             examination (including electrocardiogram [ECG]), and clinical laboratory assessments;&#xD;
&#xD;
         11. Female subjects of childbearing potential, and male subjects with partners of&#xD;
             childbearing potential, may participate if adequate contraception is used during, and&#xD;
             for at least the four weeks after administration of study medication&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Diagnosed with RA prior to 16 years of age;&#xD;
&#xD;
          2. Women who are pregnant, breastfeeding, or have a positive serum pregnancy test at&#xD;
             screening;&#xD;
&#xD;
          3. History within one year prior to randomization of illicit drug use;&#xD;
&#xD;
          4. History of alcohol abuse at any time in the past;&#xD;
&#xD;
          5. Have received sulfasalazine, azathioprine, 6-mercaptopurine, mycophenolate mofetil,&#xD;
             tetracycline, cyclosporine, gold, tacrolimus, sirolimus, or other disease modifying&#xD;
             anti-rheumatic drug (DMARD) within 8 weeks of randomization;&#xD;
&#xD;
          6. Use of infliximab, adalimumab, abatacept, certolizumab, golimumab, or tocilizumab&#xD;
             within 8 weeks of randomization;&#xD;
&#xD;
          7. Use of leflunomide within 6 months of randomization;&#xD;
&#xD;
          8. Use of etanercept or anakinra within 4 weeks of randomization;&#xD;
&#xD;
          9. Use of a B-cell depleting agent such as rituximab or ocrelizumab, or cytotoxic agents,&#xD;
             such as cyclophosphamide or chlorambucil, within one year of randomization;&#xD;
&#xD;
         10. Currently taking cytochrome P450 inhibitors including protease inhibitors such as&#xD;
             ritonavir, indinavir, nelfinavir, or macrolide antibiotics such as erythromycin,&#xD;
             telithromycin, clarithromycin, or azole antifungals such as fluconazole, ketoconazole,&#xD;
             itraconazole, or cimetidine, nefazodone, bergamottin (constituent of grapefruit&#xD;
             juice), quercetin, aprepitant, or verapamil;&#xD;
&#xD;
         11. Currently taking cytochrome P450 inducers including St. John's wort, rifampicin,&#xD;
             rifabutin, rifapentin, dexamethasone, phenytoin, carbamazapine, phenobarbitol, or&#xD;
             troglitazone;&#xD;
&#xD;
         12. Intra-articular, intravenous, or intramuscular corticosteroid injection within 4 weeks&#xD;
             of randomization;&#xD;
&#xD;
         13. History or presence of any form of cancer within the 10 years prior to randomization,&#xD;
             with the exception of excised basal cell or squamous cell carcinoma of the skin, or&#xD;
             cervical carcinoma in situ or breast carcinoma in situ that has been excised or&#xD;
             resected completely and is without evidence of local recurrence or metastasis;&#xD;
&#xD;
         14. Evidence of tuberculosis (TB) based on chest X rays, tuberculin skin test,&#xD;
             QuantiFERON®-TB Gold test, or T-SPOT®.&#xD;
&#xD;
         15. Presence of Felty's syndrome, psoriatic arthritis, gout, or other auto-immune&#xD;
             diseases;&#xD;
&#xD;
         16. Major surgery (including joint surgery) within 12 weeks prior to randomization;&#xD;
&#xD;
         17. The subject had an infection requiring antibiotic treatment within 4 weeks of&#xD;
             randomization;&#xD;
&#xD;
         18. Subject has any evidence of hepatic disease; Aspartate Aminotransferase (AST), Alanine&#xD;
             Aminotransferase (ALT), alkaline phosphatase, or bilirubin &gt; 1.5 x the upper limit of&#xD;
             normal;&#xD;
&#xD;
         19. Subject has any evidence of renal impairment; serum creatinine &gt; 1.5 x upper limit of&#xD;
             normal or estimated Glomerular Filtration Rate (GFR) based on the Cockcroft-Gault&#xD;
             equation &lt; 30 mL/min;&#xD;
&#xD;
         20. History or presence of any medical or psychiatric condition or disease, or laboratory&#xD;
             abnormality that, in the opinion of the Investigator, may place the subject at&#xD;
             unacceptable risk for study participation and may prevent the subject from completing&#xD;
             the study&#xD;
&#xD;
         21. Participated in any clinical study of an investigational product including CCX354-C&#xD;
             within 30 days or 5 times the half life of the agent, whichever is longer, prior to&#xD;
             randomization&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pirow Bekker, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>ChemoCentryx, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kortrijik</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Liege</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Brno</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bruntal</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hlucin</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ostrava-Trebovice</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Prague</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Uherske Hradiste</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Zlin</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Frankfurt</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hannover</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Herne</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Leipzig</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mainz</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wurzburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Balatonfured</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bekescsaba</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Szekesfehervar</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Veszprem</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chelm Slaski</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Elblag</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Grodzisk Mazowiecki</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Krakow</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lublin</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Poznan</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Warsaw</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Zyrardow</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bacau</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Baia Mare</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Braila</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Galati</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St. Gheorghe, Covasna</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Targoviste</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Donetsk</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kharkov</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kiev</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Czech Republic</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>Ukraine</country>
  </location_countries>
  <verification_date>February 2012</verification_date>
  <study_first_submitted>November 15, 2010</study_first_submitted>
  <study_first_submitted_qc>November 16, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 17, 2010</study_first_posted>
  <last_update_submitted>February 8, 2012</last_update_submitted>
  <last_update_submitted_qc>February 8, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 9, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

